Utilizing the ACCE framework, we previously reported on the analytical validity of OncuriaTM, a quantitative multiplex immunoassay capable of evaluating voided urine samples for the following biomarkers: angiogenin (ANG), apolipoprotein E (APOE), alpha-1 antitrypsin (A1AT), carbonic anhydrase 9 (CA9), interleukin-8 (IL-8), matrix metallopeptidase 9 (MMP9), matrix metallopeptidase 10 (MMP10), plasminogen activator inhibitor 1 (PAI1), syndecan 1 (SDC1), and vascular endothelial growth factor (VEGF), all of which comprised a validated bladder-cancer-associated diagnostic signature [4]. This evidence concerns the gene MMP9 and urinary bladder cancer.